# An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

> **NCT04876313** · PHASE2 · UNKNOWN · sponsor: **IRCCS San Raffaele** · enrollment: 29 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma

## Interventions

- **DRUG:** Nivolumab + Nab-paclitaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04876313
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-27
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876313, "An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04876313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*